vs
Esperion Therapeutics, Inc.（ESPR）与Proto Labs Inc（PRLB）财务数据对比。点击上方公司名可切换其他公司
Esperion Therapeutics, Inc.的季度营收约是Proto Labs Inc的1.2倍（$168.4M vs $136.5M），Esperion Therapeutics, Inc.同比增速更快（143.7% vs 12.1%），过去两年Esperion Therapeutics, Inc.的营收复合增速更高（10.6% vs 3.3%）
Esperion Therapeutics, Inc.是一家上市美国药企，专注开发用于降低低密度脂蛋白胆固醇的口服小分子药物苯哌多酸，公司总部位于密歇根州安娜堡，目前核心研发管线围绕这款降脂创新药物推进，深耕血脂异常治疗领域的创新药物开发。
Proto Labs是一家提供快速制造服务的企业，可通过3D打印、CNC加工、钣金加工以及注塑成型工艺，为客户生产用于原型制作和量产的定制零部件，产品广泛应用于医疗设备、航空航天、电子、家电、汽车、消费品等多个领域，公司总部位于美国明尼苏达州，在美国多地设有生产基地。
ESPR vs PRLB — 直观对比
营收规模更大
ESPR
是对方的1.2倍
$136.5M
营收增速更快
ESPR
高出131.6%
12.1%
两年增速更快
ESPR
近两年复合增速
3.3%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $168.4M | $136.5M |
| 净利润 | — | — |
| 毛利率 | — | 44.2% |
| 营业利润率 | 50.6% | 5.0% |
| 净利率 | — | — |
| 营收同比 | 143.7% | 12.1% |
| 净利润同比 | — | — |
| 每股收益（稀释后） | $0.32 | $0.25 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ESPRPRLB
| Q4 25 | $168.4M | $136.5M | ||
| Q3 25 | $87.3M | $135.4M | ||
| Q2 25 | $82.4M | $135.1M | ||
| Q1 25 | $65.0M | $126.2M | ||
| Q4 24 | $69.1M | $121.8M | ||
| Q3 24 | $51.6M | $125.6M | ||
| Q2 24 | $73.8M | $125.6M | ||
| Q1 24 | $137.7M | $127.9M |
净利润ESPRPRLB
| Q4 25 | — | — | ||
| Q3 25 | $-31.3M | $7.2M | ||
| Q2 25 | $-12.7M | $4.4M | ||
| Q1 25 | $-40.5M | $3.6M | ||
| Q4 24 | — | — | ||
| Q3 24 | $-29.5M | $7.2M | ||
| Q2 24 | $-61.9M | $4.5M | ||
| Q1 24 | $61.0M | $5.3M |
毛利率ESPRPRLB
| Q4 25 | — | 44.2% | ||
| Q3 25 | — | 45.3% | ||
| Q2 25 | — | 44.3% | ||
| Q1 25 | — | 44.1% | ||
| Q4 24 | — | 42.7% | ||
| Q3 24 | — | 45.6% | ||
| Q2 24 | — | 45.0% | ||
| Q1 24 | — | 44.9% |
营业利润率ESPRPRLB
| Q4 25 | 50.6% | 5.0% | ||
| Q3 25 | -11.4% | 6.5% | ||
| Q2 25 | 8.6% | 3.7% | ||
| Q1 25 | -34.0% | 3.6% | ||
| Q4 24 | -6.4% | -1.2% | ||
| Q3 24 | -31.0% | 6.8% | ||
| Q2 24 | 3.5% | 4.8% | ||
| Q1 24 | 52.5% | 5.3% |
净利率ESPRPRLB
| Q4 25 | — | — | ||
| Q3 25 | -35.9% | 5.3% | ||
| Q2 25 | -15.4% | 3.3% | ||
| Q1 25 | -62.2% | 2.9% | ||
| Q4 24 | — | — | ||
| Q3 24 | -57.2% | 5.7% | ||
| Q2 24 | -83.9% | 3.6% | ||
| Q1 24 | 44.3% | 4.1% |
每股收益（稀释后）ESPRPRLB
| Q4 25 | $0.32 | $0.25 | ||
| Q3 25 | $-0.16 | $0.30 | ||
| Q2 25 | $-0.06 | $0.18 | ||
| Q1 25 | $-0.21 | $0.15 | ||
| Q4 24 | $-0.14 | $-0.01 | ||
| Q3 24 | $-0.15 | $0.29 | ||
| Q2 24 | $-0.33 | $0.18 | ||
| Q1 24 | $0.34 | $0.20 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $167.9M | $128.1M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $-302.0M | $673.9M |
| 总资产 | $465.9M | $763.4M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资ESPRPRLB
| Q4 25 | $167.9M | $128.1M | ||
| Q3 25 | $92.4M | $119.2M | ||
| Q2 25 | $86.1M | $103.2M | ||
| Q1 25 | $114.6M | $96.8M | ||
| Q4 24 | $144.8M | $103.1M | ||
| Q3 24 | $144.7M | $100.5M | ||
| Q2 24 | $189.3M | $112.9M | ||
| Q1 24 | $226.6M | $109.7M |
股东权益ESPRPRLB
| Q4 25 | $-302.0M | $673.9M | ||
| Q3 25 | $-451.4M | $664.7M | ||
| Q2 25 | $-433.5M | $664.7M | ||
| Q1 25 | $-426.2M | $656.8M | ||
| Q4 24 | $-388.7M | $670.2M | ||
| Q3 24 | $-370.2M | $680.0M | ||
| Q2 24 | $-344.2M | $685.2M | ||
| Q1 24 | $-294.3M | $687.3M |
总资产ESPRPRLB
| Q4 25 | $465.9M | $763.4M | ||
| Q3 25 | $364.0M | $756.9M | ||
| Q2 25 | $347.1M | $743.3M | ||
| Q1 25 | $324.0M | $737.5M | ||
| Q4 24 | $343.8M | $743.5M | ||
| Q3 24 | $314.1M | $753.8M | ||
| Q2 24 | $352.3M | $758.2M | ||
| Q1 24 | $373.1M | $769.8M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $45.2M | $16.5M |
| 自由现金流经营现金流 - 资本支出 | — | $8.4M |
| 自由现金流率自由现金流/营收 | — | 6.2% |
| 资本支出强度资本支出/营收 | 0.0% | 5.9% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | $59.7M |
8季度趋势，按日历期对齐
经营现金流ESPRPRLB
| Q4 25 | $45.2M | $16.5M | ||
| Q3 25 | $-4.3M | $29.1M | ||
| Q2 25 | $-31.4M | $10.6M | ||
| Q1 25 | $-22.6M | $18.4M | ||
| Q4 24 | $-35.0M | $17.3M | ||
| Q3 24 | $-35.3M | $24.8M | ||
| Q2 24 | $-7.2M | $14.4M | ||
| Q1 24 | $53.8M | $21.3M |
自由现金流ESPRPRLB
| Q4 25 | — | $8.4M | ||
| Q3 25 | — | $25.0M | ||
| Q2 25 | — | $9.1M | ||
| Q1 25 | — | $17.1M | ||
| Q4 24 | — | $16.5M | ||
| Q3 24 | $-35.5M | $23.2M | ||
| Q2 24 | $-7.3M | $10.2M | ||
| Q1 24 | $53.8M | $18.8M |
自由现金流率ESPRPRLB
| Q4 25 | — | 6.2% | ||
| Q3 25 | — | 18.5% | ||
| Q2 25 | — | 6.7% | ||
| Q1 25 | — | 13.6% | ||
| Q4 24 | — | 13.5% | ||
| Q3 24 | -68.7% | 18.5% | ||
| Q2 24 | -9.9% | 8.2% | ||
| Q1 24 | 39.0% | 14.7% |
资本支出强度ESPRPRLB
| Q4 25 | 0.0% | 5.9% | ||
| Q3 25 | 0.0% | 3.0% | ||
| Q2 25 | 0.0% | 1.1% | ||
| Q1 25 | 0.0% | 1.0% | ||
| Q4 24 | 0.0% | 0.7% | ||
| Q3 24 | 0.3% | 1.2% | ||
| Q2 24 | 0.1% | 3.3% | ||
| Q1 24 | 0.1% | 2.0% |
现金转化率ESPRPRLB
| Q4 25 | — | — | ||
| Q3 25 | — | 4.03× | ||
| Q2 25 | — | 2.39× | ||
| Q1 25 | — | 5.11× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 3.44× | ||
| Q2 24 | — | 3.18× | ||
| Q1 24 | 0.88× | 4.05× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ESPR
| Collaboration Revenue | $124.7M | 74% |
| Products | $43.7M | 26% |
PRLB
| CNC Machining Firstcut | $65.5M | 48% |
| Injection Molding Protomold | $47.6M | 35% |
| Three D Printing Fineline | $18.8M | 14% |
| Sheet Metal | $4.4M | 3% |
